Want to see ABUS full AI Analyst Report?
ABUS Stock Chart & Stats
$4.38
$0.07(1.60%)
At close: 4:00 PM EDT
$4.38
$0.07(1.60%)
Day’s Range― - ―
52-Week Range$3.26 - $5.38
Previous CloseN/A
Volume126.53K
Average Volume (3M)2.56M
Market Cap
$857.31M
Enterprise Value$787.15
Total Cash (Recent Filing)$95.23M
Total Debt (Recent Filing)$3.91M
Price to Earnings (P/E)5.2
Beta0.35
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.83
Shares Outstanding197,537,700
10 Day Avg. Volume1,686,205
30 Day Avg. Volume2,555,084
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)12.04
Price to Sales (P/S)65.44
P/FCF Ratio-23.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.75
Revenue Forecast (FY)$181.17M
Bulls Say, Bears Say
Bulls Say
Financial ManagementArbutus ended 2024 with $123M in cash and highlighted a 'continued focus on efficient deployment of financial resources and personnel.'
Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.
Product DevelopmentAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.
Bears Say
Clinical TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.
Legal ChallengesArbutus and partner Genevant expand their LNP legal activity against Moderna globally.
Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.
Arbutus Biopharma News
ABUS FAQ
What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest stock price was $3.26 and its highest was $5.38 in the past 12 months.
What is Arbutus Biopharma’s market cap?
Arbutus Biopharma’s market cap is $857.31M.
When is Arbutus Biopharma’s upcoming earnings report date?
Arbutus Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 100 days.
How were Arbutus Biopharma’s earnings last quarter?
Currently, no data Available
Is Arbutus Biopharma overvalued?
According to Wall Street analysts Arbutus Biopharma’s price is currently Overvalued.
Does Arbutus Biopharma pay dividends?
Arbutus Biopharma does not currently pay dividends.
What is Arbutus Biopharma’s EPS estimate?
Arbutus Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arbutus Biopharma have?
Arbutus Biopharma has 197,537,700 shares outstanding.
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arbutus Biopharma?
Currently, no hedge funds are holding shares in ABUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arbutus Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 476.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
136.87%
Trailing 12-Months
Company Description
Arbutus Biopharma
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Technical Analysis
Ownership Overview
0.05% Insiders
9.61% Mutual Funds
0.50% Other Institutional Investors
77.53% Public Companies and
Individual Investors